Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

From Baxter International Inc. 9 Mar 2015

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online in JAMA Oncology.

28 Feb 2015

MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

The University of Texas MD Anderson Cancer Center returns March 7 to Sarasota, Fla., for the institution's annual Making Cancer History® seminar at the Hyatt Regency Sarasota, 1000 Blvd. of the Arts.

17 Feb 2015

Tissue and cell diagnostics market reaches $7.7 billion in 2014

With fast and effective testing techniques, the tissue and cell diagnostics market was estimated to have reached $7.7 billion in 2014 for in vitro diagnostic (IVD) and other reagents used by clinical laboratories, according to Kalorama Information.

16 Feb 2015

CLL aggressiveness linked to genetic variability

The genetic variability of a tumour could be a predictor for its aggressiveness: the greater the variability in gene expression, the more aggressive the tumour is likely to be. This is the hypothesis that the CNIO Structural Biology and Biocomputing Programme, led by Alfonso Valencia, is testing, after their findings on chronic lymphocytic leukaemia (CLL), now published in the journal Genome Medicine.

6 Feb 2015

FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

The U.S. Food and Drug Administration approval of ibrutinib (Imbruvica) to treat patients with Waldenstrom's macroglobulinemia(WM) is a significant advance for patients with this rare blood cancer.

31 Jan 2015

ASCO announces cancer Advance of the Year

The American Society of Clinical Oncology for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.

20 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).

15 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

Study finds that disarray in methylation helps tumors adapt to changing circumstances

The genetic tumult within cancerous tumors is more than matched by the disorder in one of the mechanisms for switching cells' genes on and off, scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

8 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation.

2 Dec 2014

Chronic Lymphocytic Leukemia News and Research

Further Reading

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

MD Anderson Cancer Center to host annual Making Cancer History seminar in Sarasota

Tissue and cell diagnostics market reaches $7.7 billion in 2014

CLL aggressiveness linked to genetic variability

FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

ASCO announces cancer Advance of the Year

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Study finds that disarray in methylation helps tumors adapt to changing circumstances

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Researchers identify new targets for future CLL therapies

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News